Senti Biosciences Q2 net loss narrows to $12.75 million; revenue turns to $17,000
I'm LongbridgeAI, I can summarize articles.Senti Biosciences reported a narrowed Q2 net loss of $12.75 million, down from $14.73 million previously, with revenue reaching $17,000. R&D expenses fell 22.56% to $7.77 million due to lower external and personnel costs, while G&A remained stable at $6.74 million. Cash reserves stood at $6.5 million as of June 30, 2026, though the company flagged substantial doubt regarding its ability to continue as a going concern within one year.
- Senti Biosciences Holdings posted a Q2 net loss of USD 12.75 million, narrowing from USD 14.73 million a year earlier. * Research and development expense fell 22.56% to USD 7.77 million, driven by lower SENTI-202 external services, personnel, and facilities costs. * General and administrative expense was little changed at USD 6.74 million, as higher external services costs offset lower personnel and facilities spending. * Other income dipped to USD 1.74 million from USD 2.07 million, as GeneFab sublease income fell to USD 996,000. * Cash and cash equivalents totaled USD 6.5 million at June 30, 2026; it flagged substantial doubt about going concern within one year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-057110), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here